191
Views
7
CrossRef citations to date
0
Altmetric
Research Article

NPM–RAR, not the RAR–NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation

, &
Pages 1383-1387 | Received 31 Jan 2013, Accepted 22 Jul 2013, Published online: 18 Sep 2013
 

Abstract

The t(5;17) variant of acute promyelocytic leukemia (APL) fuses the nucleophosmin (NPM) gene at 5q35 with the retinoic acid receptor alpha (RARA) at 17q12-22. We have previously shown that leukemic cells express both NPM–RAR and RAR– NPM reciprocal translocation products. In this study we investigated the potential role of both proteins in modulating myeloid differentiation. Expression of NPM–RAR inhibited vitamin D3/transforming growth factor β (TGFβ)-mediated differentiation of U937 cells by more than 50%. In contrast, RAR–NPM expression did not alter vitamin D3/TGFβ-induced differentiation of U937 clones. These results indicate that NPM–RAR, not RAR–NPM, is the prime mediator of myeloid differentiation arrest in t(5;17) APL.

Acknowledgements

The authors would like to thank Richard Steinman, MD, PhD and Daniel Johnson, PhD for valuable discussions. This work was supported by NIH R01 CA67346 and P30 CA047904.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.